Diabetes Mellitus After Intensive Care Admission (DIAFIC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02180555|
Recruitment Status : Unknown
Verified July 2014 by Christophe De Block, University Hospital, Antwerp.
Recruitment status was: Recruiting
First Posted : July 2, 2014
Last Update Posted : July 8, 2014
|Condition or disease||Intervention/treatment|
|Stress Hyperglycemia Diabetes Mellitus||Other: Oral glucose tolerance test|
|Study Type :||Observational|
|Estimated Enrollment :||400 participants|
|Official Title:||Incidence and Predisposing Factors for the Development of Glucose Metabolism Disturbances and Diabetes Mellitus After Intensive Care Admission|
|Study Start Date :||February 2012|
|Estimated Primary Completion Date :||July 2015|
Other: Oral glucose tolerance test
- Glucose metabolism disturbance [ Time Frame: 6-9 months after ICU discharge ]At a follow-up visit, patients will have their blood glucose levels sampled both after fasting and 2 hours after an oral glucose tolerance test (OGTT). HbA1c levels will be sampled once as well. Possible disturbances in glucose metabolism are the following: isolated impaired fasting glucose (IFG) = fasting plasma glucose (FPG) level of 100-125 mg/dl with the 2-h value after OGTT <140 mg/dl. Isolated impaired glucose tolerance (IGT) = 2-h value after OGTT of 140-199 mg/dl with the fasting level <100 mg/dl. Patients with combined characteristics of IFG and IGT fulfill both criteria (FPG = 100-125 mg/dl and 2-h value after OGTT = 140-199 mg/d). Diabetes mellitus is diagnosed when a patient has one of the following criteria: FPG more or equal to 126mg/dl, 2-h value after OGTT more or equal to 200 mg/dl, HbA1c more or equal to 6.5%.
- Patient characteristics predicting adverse outcome [ Time Frame: 6-9 months after ICU discharge ]We will assess the effect of the patient's length, weight, body mass index (BMI), reason for admission, preadmission home medication, treatment during admission (steroids, vasopressors, inotropics, mechanical ventilation, insulin, total parenteral nutrition (TPN), laboratory values including blood glucose and HbA1c on intensive care unit (ICU) admission on our primary outcome parameter. Moreover, we will take into account the Simplified Acute Physiology Score (SAPS-3) and the daily Sequential Organ Failure Assessment (SOFA) score as parameters for disease severity, together with vasopressor or inotropic therapy, mechanical ventilation and length of stay at the hospital and ICU. Furthermore, our patients will complete the Finnish Diabetes Risk Score (FINDRISC) questionnaire during their follow-up visit, and we will compare this result with the primary outcome parameter as well.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02180555
|Contact: Philippe G Jorens, MD, PhD||00323821 ext firstname.lastname@example.org|
|Antwerp University Hospital||Recruiting|
|Edegem, Antwerpen, Belgium, 2650|
|Contact: Philippe G Jorens, MD, PhD 00323821 ext 3635|
|Sub-Investigator: Walter Verbrugghe, MD|
|Sub-Investigator: Tom Schepens, MD PhD|
|Sub-Investigator: Karolien Janssens, MD|
|Principal Investigator: Christophe De Block, MD, PhD|
|Sub-Investigator: Sofie Van Ackerbroeck, MD|
|Sub-Investigator: Philippe G Jorens, MD, PhD|